Global biopharmaceutical firm Harbour BioMed (HBM) announced on Thursday the completion of a Series B+ round of financing at $75 million to accelerate the advancement of its clinical-stage compounds and next-generation biotherapeutics for treating cancer and immunological diseases.
New investors in the Series B+ round include South Korea’s SK Holdings, Chinese venture capital firm Efung Capital, Hangzhou-based Zheshang Venture Capital (ZSVC), Zhejiang University Future Capital, Greater Bay Area Fund, and JT New Century, according to a statement.
